NCT06800092View on ClinicalTrials.gov

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2030

Conditions

Cancer

Interventions

DRUG

Sildenafil

Sildenafil, 50mg, daily

Trial Locations (1)

77555

RECRUITING

The University of Texas Medical Branch, Galveston

All Listed Sponsors

lead

The University of Texas Medical Branch, Galveston

OTHER